<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gestational diabetes mellitus: Screening, diagnosis, and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gestational diabetes mellitus: Screening, diagnosis, and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gestational diabetes mellitus: Screening, diagnosis, and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Celeste Durnwald, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David M Nathan, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erika F Werner, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pregnancy is generally a state of both enhanced beta-cell function and insulin resistance, mediated primarily by placental secretion of diabetogenic hormones including growth hormone, corticotropin-releasing hormone, placental lactogen (chorionic somatomammotropin), prolactin, and progesterone. These and other metabolic changes, which are most prominent in the third trimester, ensure that the fetus has an ample supply of nutrients.</p><p>Gestational diabetes mellitus (GDM) develops in pregnant people whose pancreatic beta-cell function is insufficient to overcome the insulin resistance associated with the pregnant state. Among the main consequences of GDM are increased risks of preeclampsia, large for gestational age (LGA) newborns, and cesarean birth, and their associated morbidities. Patients with GDM are at high risk of developing type 2 diabetes later in life, which is not surprising since both disorders are characterized by inadequate insulin secretion in the setting of insulin resistance. In contrast to diabetes that develops pregestationally, GDM is not generally associated with an increased risk for congenital anomalies since hyperglycemia develops after organ formation is complete.</p><p>There is no universally accepted standard regarding screening for or diagnosis of GDM. Practitioners tend to follow the guidance of their national medical organizations. Approaches to screening and diagnosis will be reviewed here. Medical and obstetric management and prognosis are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4800.html" rel="external">"Gestational diabetes mellitus: Obstetric issues and management"</a>.)</p><p></p><p class="headingAnchor" id="H132644621"><span class="h1">TERMINOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gestational diabetes</strong> traditionally referred to any pregnant person in whom abnormal glucose tolerance was first recognized at any time during pregnancy [<a href="#rid1">1</a>]. A more contemporary definition, and that used by the American Diabetes Association (ADA), is diabetes diagnosed in the second or third trimester that was not clearly overt diabetes prior to conception [<a href="#rid2">2</a>]. This definition excludes patients diagnosed in the first trimester because they likely have previously undiagnosed type 2 diabetes. The term "overt diabetes" is sometimes used to describe the diabetes status of these individuals during pregnancy; a formal diagnosis of type 2 diabetes can be made when the diagnosis is confirmed in the nonpregnant state. </p><p></p><p class="bulletIndent1">The American College of Obstetricians and Gynecologists (ACOG) continues to define GDM as "a condition in which carbohydrate intolerance develops during pregnancy" [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preexisting or pregestational diabetes</strong> refers to type 1 or 2 diabetes diagnosed before pregnancy.</p><p></p><p class="headingAnchor" id="H473902738"><span class="h1">BACKGROUND</span></p><p class="headingAnchor" id="H1819068"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The prevalence of GDM by the traditional Carpenter and Coustan criteria  (<a class="graphic graphic_table graphicRef80677" href="/d/graphic/80677.html" rel="external">table 3B</a>) [<a href="#rid4">4</a>] was 7.8 percent of births in the United States in 2020 [<a href="#rid5">5</a>] and ranged from 2 to 38 percent of pregnant people in other countries [<a href="#rid6">6</a>]. Worldwide prevalence varies because of differences in population characteristics (eg, average maternal age and body mass index [BMI]) and choice of screening and diagnostic criteria. Using the 2010 International Association of Diabetes and Pregnancy Study Groups (IADPSG) screening and diagnostic criteria for diabetes in pregnancy  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>) [<a href="#rid7">7</a>], the global prevalence of GDM has been estimated to be 17 percent, with regional estimates of 10 percent in North America and 25 percent in Southeast Asia [<a href="#rid8">8</a>].</p><p>Prevalence has been increasing over time, likely due to increases in mean maternal age and BMI, particularly increasing obesity, and changes in screening practices and methods [<a href="#rid9">9-16</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Significance</span><span class="headingEndMark"> — </span>GDM has been associated with increased risks of several adverse outcomes. (See  <a class="medical medical_review" href="/d/html/4800.html" rel="external">"Gestational diabetes mellitus: Obstetric issues and management", section on 'Consequences of GDM'</a>.) </p><p>Although treatment of GDM can reduce the risk of some short-term outcomes (eg, preeclampsia, macrosomia), a favorable effect on the long-term outcomes described below is unclear. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Rationale for treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Short-term</strong> – GDM has been associated with increased risks of the following problems, some of which are interdependent [<a href="#rid17">17-21</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertensive disorders of pregnancy (preeclampsia, gestational hypertension) </p><p class="bulletIndent2"><span class="glyph">•</span>Large for gestational age (LGA) or macrosomic newborn </p><p class="bulletIndent2"><span class="glyph">•</span>Polyhydramnios</p><p class="bulletIndent2"><span class="glyph">•</span>Medically-indicated preterm birth</p><p class="bulletIndent2"><span class="glyph">•</span>Operative birth (cesarean, forceps- or vacuum-assisted vaginal)</p><p class="bulletIndent2"><span class="glyph">•</span>Shoulder dystocia </p><p class="bulletIndent2"><span class="glyph">•</span>Maternal and/or newborn birth trauma</p><p class="bulletIndent2"><span class="glyph">•</span>Fetal/neonatal cardiomyopathy</p><p class="bulletIndent2"><span class="glyph">•</span>Neonatal respiratory problems and metabolic complications (eg, hypoglycemia, hyperbilirubinemia, hypocalcemia, hypomagnesemia, polycythemia and hyperviscosity syndrome)</p><p class="bulletIndent2"><span class="glyph">•</span>Stillbirth</p><p></p><p class="bulletIndent1">Importantly, the risks of these outcomes increase as maternal fasting plasma glucose levels increase above 75 mg/dL (4.2 mmol/L) and as the one- and two-hour oral glucose tolerance test (GTT) values increase from the lowest septile to the highest. This is a continuous effect; there is no clear threshold that defines patients at increased risk of adverse obstetric outcome [<a href="#rid19">19-22</a>].</p><p></p><p class="bulletIndent1">The small increase in congenital anomalies observed in some population-based studies of GDM (odds ratio [OR] 1.18 [<a href="#rid23">23</a>]) is likely related to undiagnosed preexisting type 2 diabetes mellitus or maternal obesity [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/d/html/433.html" rel="external">"Obesity in pregnancy: Complications and maternal management", section on 'Congenital anomalies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Long-term </strong>– GDM has also been associated with increased long-term risks:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal – Development of diabetes mellitus (primarily type 2), metabolic syndrome, and cardiovascular disease. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Long-term risk'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adolescent and adult offspring – Obesity, abnormal glucose tolerance, hypertension, and metabolic syndrome. An increased risk of adverse neurodevelopmental outcomes has also been reported and may be related to shared environmental and genetic factors; however, evidence is circumstantial and requires further study [<a href="#rid26">26-31</a>]. (See  <a class="medical medical_review" href="/d/html/5058.html" rel="external">"Infants of mothers with diabetes (IMD)", section on 'Long-term outcome'</a>.)</p><p></p><p class="headingAnchor" id="H8"><span class="h2">Risk factors</span></p><p class="headingAnchor" id="H4233476507"><span class="h3">Individuals at increased risk of GDM</span><span class="headingEndMark"> — </span>Pregnant people with any of the following characteristics appear to be at increased risk of developing GDM. The risk varies across these characteristics and is additive when multiple risk factors are present [<a href="#rid3">3,32-39</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Personal history of any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>GDM in a previous pregnancy (associated with a 40 percent risk of recurrence [<a href="#rid40">40</a>])</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired glucose tolerance</p><p class="bulletIndent2"><span class="glyph">•</span>A1C ≥5.7 percent</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated fasting glucose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of diabetes, especially in a first-degree relative.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prepregnancy BMI ≥30 kg/m<sup>2</sup>, significant weight gain in early adulthood or between pregnancies, or excessive gestational weight gain during the first 18 to 24 weeks of pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical condition/setting associated with development of diabetes (eg, polycystic ovary syndrome [PCOS]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Older maternal age (≥35 years of age).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Member of one of the following groups, which have a high prevalence of type 2 diabetes: Hispanic American; Native American, Alaska native, or Native Hawaiian; South or East Asian, Pacific Islander. The prevalence is less in non-Hispanic White and non-Hispanic Black people [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous birth of an infant ≥4000 g (approximately 9 pounds).</p><p></p><p class="headingAnchor" id="H1814747408"><span class="h3">Individuals at low risk of GDM</span><span class="headingEndMark"> — </span>By comparison, the risk of developing GDM is low in younger (&lt;25 years of age) non-Hispanic White people, with normal BMI (&lt;25 kg/m<sup>2</sup> [&lt;23 kg/m<sup>2 </sup>in Asian people]), no history of previous glucose intolerance or adverse pregnancy outcomes associated with GDM, and no first-degree relative with diabetes [<a href="#rid41">41</a>]. Only 10 percent of the general obstetric population in the United States meets all of these criteria for low risk of developing GDM, which is the basis for universal rather than selective screening [<a href="#rid42">42</a>]. (See <a class="local">'Candidates'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h3">Lifestyle interventions for risk reduction</span><span class="headingEndMark"> — </span>Lifestyle interventions (eg, diet modification, exercise) are targeted at individuals at increased risk for developing GDM, particularly those who are overweight or obese and those with a history of GDM in a previous pregnancy. The primary target of lifestyle interventions is weight loss leading to less insulin resistance and impaired insulin secretion.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diet modification and increased exercise</strong> – In a meta-analysis of randomized trials, lifestyle interventions targeted at individuals with a higher baseline risk of GDM (eg, 20 percent incidence of GDM) reduced the risk of GDM by approximately 20 percent compared with standard care [<a href="#rid43">43</a>]. The interventions included diet modification, increased exercise, or both, ideally initiated before pregnancy and continuing across gestation; exercising at the proper intensity and frequency (eg, moderate intensity for 50 to 60 minutes at least twice a week throughout pregnancy); and managing gestational weight gain so as to not exceed standard recommendations  (<a class="graphic graphic_table graphicRef75820" href="/d/graphic/75820.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1">Individuals who are overweight or obese appear to benefit from weight loss before conception [<a href="#rid44">44,45</a>], whereas beginning a modest unsupervised exercise program in the second trimester appears to be inadequate to impact the risk of GDM [<a href="#rid46">46-48</a>]. (See  <a class="medical medical_review" href="/d/html/412.html" rel="external">"Exercise during pregnancy and the postpartum period"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of diet</strong> – The optimum diet is unclear. There is limited evidence (none from randomized trials) that a diet favoring fruit, vegetables, whole grains, and fish and low in red and processed meat, refined grains, and high-fat dairy reduces the risk of developing GDM [<a href="#rid49">49,50</a>]. The effect of a low glycemic index diet on risk of GDM is unclear as only a few small randomized trials have been performed. A meta-analysis of these trials did not demonstrate a clear benefit, but the confidence interval was wide (risk ratio [RR] 0.91, 95% CI 0.61-1.31; four trials, 912 participants) [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Smoking cessation</strong> – Smoking cessation should be encouraged in all patients. The association between smoking and GDM is uncertain [<a href="#rid32">32,52</a>] and cessation is often associated with weight gain; cessation has multiple maternal and fetal benefits and may reduce GDM. (See  <a class="medical medical_review" href="/d/html/115306.html" rel="external">"Tobacco and nicotine use in pregnancy: Cessation strategies and treatment options"</a>.)</p><p></p><p>These interventions overlap with those utilized for prevention of type 2 diabetes and are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1774.html" rel="external">"Prevention of type 2 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H2988732701"><span class="h4">Investigational risk reduction measures of uncertain benefit</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">Metformin</a><strong> </strong>has not reduced the risk for GDM in randomized trials. Metformin has been proposed as a medication to "prevent" GDM, based in part on evidence of its effectiveness in reducing the risk for type 2 diabetes in nonpregnant individuals with prior GDM [<a href="#rid53">53</a>] and observations that it reduced the risk for GDM in patients with PCOS [<a href="#rid54">54,55</a>]. However, in a randomized trial of 273 pregnancies among 257 patients with PCOS who were assigned to receive metformin (2000 mg/day) or placebo from the first trimester until delivery, the prevalence of GDM was similar in both groups (metformin: 17.6 percent versus placebo: 16.9 percent) [<a href="#rid56">56</a>]. Two randomized trials comparing metformin with placebo in pregnant people with obesity also showed no significant reduction in the rate of GDM [<a href="#rid57">57,58</a>]. In most other metformin trials, patients in the metformin group gained less weight during pregnancy than those in the placebo group. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics </strong>do not appear to be useful and may be harmful. In a meta-analysis of randomized trials, probiotics did not clearly reduce the risk of GDM compared with placebo (mean RR 0.80, 95% CI 0.54-1.20; 6 trials, 1440 participants) but increased the risk of preeclampsia (RR 1.85, 95% CI 1.04-3.29; 4 studies, 955 participants) [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Myoinositol</strong> is a naturally occurring sugar in fruits, beans, grains, and nuts that can improve insulin resistance. A meta-analysis reported a reduction in GDM with supplementation (RR 0.53, 95% CI 0.31-0.90; 6 trials, 1140 participants), but limitations include individual small studies, lack of generalizability, and inconsistency, which may be related to different doses, timing, and combinations of myoinositol supplementation [<a href="#rid60">60</a>]. Before this intervention can be recommended, a large multicenter, blinded, randomized trial is needed to confirm safety and demonstrate improvement in clinically important maternal and/or neonatal outcomes.</p><p></p><p class="headingAnchor" id="H1818482"><span class="h1">BENEFITS AND HARMS OF SCREENING</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential benefits</strong> – A 2021 systematic review by the United States Preventive Services Task Force (USPSTF) found that screening for GDM at 24 weeks of gestation or after was associated with some favorable maternal and fetal/newborn outcomes (eg, reduction in cesarean births, birth injuries, neonatal intensive care unit admissions, stillbirth) compared with historical unscreened controls [<a href="#rid61">61,62</a>]. These findings were largely derived from two observational studies [<a href="#rid63">63,64</a>]. In addition, randomized trials have shown that treatment of GDM can reduce some fetal, neonatal, and maternal morbidities, particularly macrosomia and shoulder dystocia, and possibly preeclampsia [<a href="#rid61">61,62</a>]. These data are described separately. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Rationale for treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential harms </strong>– The commonly used screening and diagnostic tests for diabetes involve drinking a glucose-containing beverage followed by blood glucose measurement. None of the screening or diagnostic tests are associated with serious harmful maternal or fetal effects, but the hyperosmolar drinks are poorly tolerated by some individuals since they may cause nausea and vomiting.</p><p></p><p class="bulletIndent1">If GDM is diagnosed, management involves medical nutrition therapy; an increased frequency of prenatal visits; frequent blood glucose monitoring; and the possibility of pharmacologic therapy, antenatal fetal monitoring, and induction because of diabetes status. Most of these interventions are not associated with serious harm, but antihyperglycemic drugs can be costly and can have side effects, which vary by drug and dose. Screening and diagnosis of GDM may lead to over- or undertreatment (treatment without a favorable effect on outcome) and heighten maternal anxiety, but long-term psychological harm is unlikely.</p><p></p><p>The cost implications of screening versus not screening are not clear [<a href="#rid65">65-67</a>].</p><p class="headingAnchor" id="H3897142904"><span class="h1">SCREENING FOR OVERT DIABETES IN EARLY PREGNANCY</span><span class="headingEndMark"> — </span>Diabetes diagnosed early in pregnancy has been called overt diabetes and is assumed to be previously undiagnosed type 2 diabetes. </p><p class="headingAnchor" id="H437876914"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>An increasing proportion of pregnant patients have unrecognized type 2 diabetes due to the increasing prevalence of obesity and lack of routine glucose/diabetes screening in reproductive-age individuals [<a href="#rid68">68</a>]. Approximately 30 percent of females aged 18 to 44 years in the United States are estimated to have some degree of abnormal glucose metabolism including impaired glucose tolerance and/or impaired fasting glucose (26 percent) or type 2 diabetes (4 percent) [<a href="#rid69">69</a>].</p><p>Unrecognized, untreated hyperglycemia in early pregnancy is important because it is associated with an increased risk of miscarriage and congenital anomalies [<a href="#rid70">70-72</a>]. In addition, unrecognized maternal comorbidity (eg, nephropathy, retinopathy) can have serious maternal and obstetric consequences. If these individuals are identified early in pregnancy, they could benefit from receiving the diagnostic and therapeutic interventions routinely provided to pregnant patients with preexisting (pregestational) diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p class="headingAnchor" id="H3554861951"><span class="h2">Our approach to early pregnancy screening (universal screening by A1C)</span><span class="headingEndMark"> — </span>Given the increasing frequency of type 2 diabetes and evidence of a reduced risk of large for gestational age (LGA) newborns with universal early maternal screening and treatment [<a href="#rid73">73</a>], the author of this topic checks an A1C level to screen for diabetes as part of the routine prenatal laboratory studies of all patients at the initial prenatal visit.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>A1C ≥6.5 percent (≥48 mmol/mol)</strong> – In nonpregnant people, an A1C ≥6.5 percent (≥48 mmol/mol) is one of the criteria used to diagnose diabetes  (<a class="graphic graphic_table graphicRef61853" href="/d/graphic/61853.html" rel="external">table 2</a>). Therefore, an A1C ≥6.5 percent early in pregnancy, when A1C levels are generally slightly lower than in the nonpregnant state [<a href="#rid74">74</a>], strongly suggests previously undiagnosed type 2 diabetes. These patients are managed similar to those with preexisting diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a> and  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a> and  <a class="medical medical_review" href="/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>A1C &lt;6.5 percent (&lt;48 mmol/mol)</strong> – This is a negative test for diabetes in nonpregnant people. At 24 to 28 weeks of gestation, the author screens these patients for GDM with the two-step test. Approximately one-quarter of pregnant people with A1C 5.7 to 6.4 percent (39 to 47 mmol/mol) suggestive of impaired glucose intolerance in early pregnancy are diagnosed with GDM when screened with a two-step test later in pregnancy compared with &lt;10 percent of those with A1C &lt;5.7 percent (39 mmol/mol) [<a href="#rid75">75</a>]. (See <a class="local">'One- and two-step approaches'</a> below.)</p><p></p><p class="bulletIndent1">The author acknowledges that an A1C &lt;6.5 percent (&lt;48 mmol/mol) is not sufficiently sensitive to detect mildly impaired glucose tolerance, especially if the A1C is ≥5.7 (which is above the upper limit of normal in nonpregnant individuals), but the overall value of detecting and treating mildly impaired glucose tolerance in early pregnancy has not been established in randomized trials [<a href="#rid76">76</a>].</p><p></p><p class="headingAnchor" id="H1823463096"><span class="h2">Other approaches to early pregnancy screening</span></p><p class="headingAnchor" id="H3582010382"><span class="h3">Targeted screening of individuals at high risk</span><span class="headingEndMark"> — </span>The International Association of Diabetes and Pregnancy Study Groups (IADPSG) [<a href="#rid7">7</a>], the American Diabetes Association (ADA) [<a href="#rid2">2</a>], and the American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid3">3</a>] suggest targeting early pregnancy screening to individuals at increased risk of undiagnosed type 2 diabetes. However, the ADA also suggests that clinicians consider testing all individuals for undiagnosed diabetes at the first prenatal visit (or preconceptionally) [<a href="#rid2">2</a>]. In contrast, a United States Preventive Services Task Force (USPSTF) guideline concluded that available evidence was insufficient to assess the balance of benefits and harms of screening asymptomatic pregnant people for glucose intolerance before 24 weeks of gestation [<a href="#rid61">61,62</a>].</p><p>The ADA and ACOG define patients at increased risk of type 2 diabetes based on [<a href="#rid2">2,3</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>GDM in a previous pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Body mass index (BMI) ≥25 kg/m<sup>2</sup> (≥23 kg/m<sup>2</sup> in Asian Americans) <strong>plus</strong> one or more of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>First-degree relative with diabetes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-risk race/ethnicity (eg, African American, Latino, Native American, Asian American, Pacific Islander).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of cardiovascular disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hypertension (≥130/80 mmHg prepregnancy) or on therapy for hypertension.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>High-density lipoprotein cholesterol level &lt;35 mg/dL (0.90 mmol/L) and/or a triglyceride level &gt;250 mg/dL (2.82 mmol/L).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polycystic ovary syndrome (PCOS).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Physical inactivity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other clinical condition associated with insulin resistance (eg, severe obesity, acanthosis nigricans).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glycated hemoglobin ≥5.7 percent (39 mmol/mol), impaired glucose tolerance (two-hour glucose level 140 to 199 mg/dL), or impaired fasting glucose (glucose level 100 to 125 mg/dL) on a previous 75-gram oral glucose tolerance test (GTT) in the nonpregnant state.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection, exposure to high-risk medicines, history of pancreatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥35 years.</p><p></p><p>In a randomized trial, early pregnancy diabetes screening because of obesity alone (BMI ≥30 kg/m<sup>2</sup>) did not demonstrate a reduction in a composite of adverse outcomes (eg, macrosomia, primary cesarean delivery, hypertensive disease of pregnancy, shoulder dystocia, neonatal hyperbilirubinemia, or hypoglycemia) [<a href="#rid77">77</a>]. Screening was done using a 50-gram one-hour GTT followed by a 100-gram, three-hour GTT if the initial screen was ≥135 mg/dL. The trial findings were limited by the small number of participants diagnosed with early GDM (n = 29) and the timing of the early screening, which was between 14 and 20 weeks.</p><p>Targeting screening to symptomatic patients is not useful because many patients are asymptomatic or have unrecognized mild symptoms. However, those with random blood glucose values ≥200 mg/dL (11.1 mmol/L) may have symptoms of hyperglycemia (eg, increased thirst, polyuria, weight loss, blurry vision). (See  <a class="medical medical_review" href="/d/html/1812.html" rel="external">"Clinical presentation, diagnosis, and initial evaluation of diabetes mellitus in adults"</a>.) </p><p class="headingAnchor" id="H3343252603"><span class="h3">Choice of screening test</span><span class="headingEndMark"> — </span>No approach has been validated for diagnosis of diabetes in the first or early second trimester. Clinical practice varies by institution and clinician preference. Screening practice varies from a hemoglobin A1C alone, fasting glucose alone, a two-hour 75-gram oral GTT, or two-step test (one-hour 50-gram GTT followed by a three-hour 100-gram GTT if the 50-gram GTT is positive). (See <a class="local">'One- and two-step approaches'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>If a two-step test is used, <strong>ACOG criteria for diabetes</strong> are shown in the tables  (<a class="graphic graphic_table graphicRef78433 graphicRef80677" href="/d/graphic/78433.html" rel="external">table 3A-B</a>). These criteria are the <strong>same</strong> as those used for diagnosis of GDM later in pregnancy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If a one-step test is used:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>ADA criteria</strong> <strong>for diabetes</strong> are shown in the table  (<a class="graphic graphic_table graphicRef61853" href="/d/graphic/61853.html" rel="external">table 2</a>). These thresholds are the same as those used by the ADA for diagnosis of diabetes in nonpregnant people and were chosen because they correlate with development of adverse vascular events, such as retinopathy and coronary artery disease, in these individuals over time [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent2">ADA criteria for "early abnormal glucose metabolism" are fasting glucose 110 to 125 mg/dL (6.1 to 6.9 mmol/L) or A1C 5.9 to 6.4 percent (41 to 47 mmol/mol). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>IADPSG criteria</strong> <strong>for diabetes</strong> are similar to ADA criteria: A1C ≥6.5 percent, fasting blood glucose ≥126 mg/dL (7.0 mmol/L), or random plasma glucose ≥200 mg/dL (11.1 mmol/L) confirmed by fasting blood glucose or A1C at these levels.</p><p></p><p class="bulletIndent1">These criteria for diagnosis of diabetes in early pregnancy are <strong>different</strong> from those used by the ADA and IADPSG for diagnosis of GDM later in pregnancy  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>).</p><p></p><p class="headingAnchor" id="H4087082564"><span class="h2">Management of patients after an early pregnancy GTT</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abnormal GTT</strong> – If a patient in early pregnancy (before significant insulin resistance) meets ADA  (<a class="graphic graphic_table graphicRef61853" href="/d/graphic/61853.html" rel="external">table 2</a>) or IADPSG criteria for diagnosis of diabetes in the nonpregnant state, they are assumed to have had the disorder prior to the pregnancy and their management is similar to those with documented preexisting diabetes mellitus in pregnancy. (See  <a class="medical medical_review" href="/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a> and  <a class="medical medical_review" href="/d/html/4802.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Antenatal glycemic control"</a> and  <a class="medical medical_review" href="/d/html/4806.html" rel="external">"Pregestational (preexisting) diabetes mellitus: Obstetric issues and management"</a>.)</p><p></p><p class="bulletIndent1">The benefit of treating a patient whose early pregnancy GTT meets ADA and IADPSG criteria for GDM  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>) has not been established. A randomized trial including over 800 pregnant participants with an abnormal two-hour 75-gram oral GTT (defined as fasting glucose level ≥92 mg/dL [≥5.1 mmol/L], one-hour glucose level ≥180 mg/dL [≥10.0 mmol/L], or a two-hour glucose level ≥153 mg/dL [≥8.5 mmol per liter]) before 20 weeks of gestation compared immediate treatment versus retesting at 24 to 28 weeks and starting treatment at that time if results were abnormal [<a href="#rid76">76</a>]. Those discovered to have overt diabetes at early testing were excluded from randomization (overt diabetes: fasting glucose level ≥110 mg/dL [≥6.1 mmol/L] or two-hour glucose level ≥200 mg/dL [11.1 mmol/L]) and treated. </p><p></p><p class="bulletIndent1">Immediate treatment of patients who meet diagnostic criteria for GDM early in pregnancy did not result in a clear or substantial reduction in LGA births (16.8 versus 19.6 percent; RR 0.77, 95% CI 0.51-1.17), composite adverse neonatal outcome (24.9 versus 30.5 percent; RR 0.82, 95% CI 0.68-0.98), or pregnancy-related hypertension (10.6 versus 9.9 percent; RR 1.08, 95% CI 0.85-1.38). The modest reduction in adverse neonatal outcome was largely due to a reduction in neonatal respiratory distress, which was unexpected. In addition, one-third of participants in the untreated early abnormal test group had normal results when retested at 24 to 28 weeks. These findings have prompted stakeholders to review their early pregnancy diabetes screening protocols, but revised guidelines from major medical organizations have not been published.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal GTT</strong> – Patients with normal 75- or 100-gram oral GTT in early pregnancy are screened for GDM at 24 to 28 weeks of gestation. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who were screened early in pregnancy by the one-step approach are rescreened using the 75-gram oral GTT. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those who were screened early in pregnancy by the two-step approach can omit the first step (50-gram oral glucose solution with glucose testing after one hour) at 24 to 28 weeks as it is likely to be abnormal; these patients can be rescreened using the three-hour 100-gram oral GTT alone [<a href="#rid78">78,79</a>] . </p><p></p><p class="headingAnchor" id="H11"><span class="h1">SCREENING FOR GDM AT 24 TO 28 WEEKS</span></p><p class="headingAnchor" id="H1973094698"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>In the United States, universal screening appears to be the most practical approach because:</p><p class="bulletIndent1"><span class="glyph">●</span>90 percent of pregnant people have at least one risk factor for glucose impairment during pregnancy, so limiting testing to those with risk factors would not substantially reduce testing [<a href="#rid42">42</a>] (see <a class="local">'Risk factors'</a> above). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>20 percent of pregnant people with GDM have no risk factors, so limiting testing to those with risk factors would miss most cases of GDM [<a href="#rid80">80-82</a>].</p><p></p><p class="headingAnchor" id="H394519025"><span class="h2">One- and two-step approaches</span><span class="headingEndMark"> — </span>Screening is performed at 24 to 28 weeks of gestation since 24 weeks is the gestational age when insulin resistance is significantly increasing, leading to hyperglycemia in those with insufficient insulin secretory capacity to maintain euglycemia [<a href="#rid2">2,3</a>]. It can be performed as a one- or two-step process. There is no consensus among national and international organizations for the optimal approach, and the choice generally depends on local customs.</p><p class="headingAnchor" id="H1292717117"><span class="h3">One-step test</span><span class="headingEndMark"> — </span>The one-step approach simplifies screening by performing only a diagnostic test, typically a fasting 75-gram oral glucose tolerance test (GTT), in all patients. The criteria for diagnosis of GDM are shown in the table  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>). The International Association of Diabetes and Pregnancy Study Groups (IADPSG) prefers this approach, which has been widely adopted internationally, and the American Diabetes Association (ADA) considers it an acceptable alternative to the two-step approach [<a href="#rid2">2</a>]. The procedure is described below. (See <a class="local">'Procedures and laboratory issues'</a> below and <a class="local">'Validation of the 75-gram GTT'</a> below.)</p><p class="headingAnchor" id="H4210584154"><span class="h3">Two-step test</span><span class="headingEndMark"> — </span>In the United States, the two-step test is the most widely used approach for identifying pregnant people with GDM. It is endorsed by American College of Obstetricians and Gynecologists (ACOG) [<a href="#rid3">3</a>] and the ADA considers it an acceptable option [<a href="#rid2">2</a>]. We prefer the two-step approach because fewer patients are diagnosed and managed as GDM, without incurring an increase in adverse outcome (see <a class="local">'Evidence for choosing the two-step versus one-step approach'</a> below). The first step has the practical advantages that fasting is unnecessary and only one blood sample is required. A minority of patients need to undergo the second step (16 percent at the ≥140 mg/dL threshold in a large series [<a href="#rid83">83</a>]).</p><p class="bulletIndent1"><span class="glyph">●</span>The first step is a one-hour 50-gram oral GTT administered without regard to time of day/previous meals. Screen-positive individuals  (<a class="graphic graphic_table graphicRef78433" href="/d/graphic/78433.html" rel="external">table 3A</a>) are at increased risk for GDM so all but those with very high (≥200 mg/dL [11.1 mmol/L]) glucose values go on to have the more cumbersome second step. We use ≥135 mg/dL (7.5 mmol/L) as the cutoff for a positive test because our patient population is at high risk for developing GDM. Although there are limited data regarding the clinical benefit of this cutoff, we believe that it offers the optimum combination of sensitivity and specificity for our population. Some institutions use a cut-off of ≥130 based on their higher-risk population. A cut-off of ≥140 mg/dL (7.8 mmol/L) is another commonly used cut-off. The procedure and supporting evidence are described below. (See <a class="local">'Screening: 50-gram one-hour GTT'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The second step is a three-hour 100-gram oral GTT performed after an overnight fast; the GTT is the diagnostic test for GDM  (<a class="graphic graphic_table graphicRef80677" href="/d/graphic/80677.html" rel="external">table 3B</a>). We use Carpenter and Coustan criteria for an abnormal GTT as the lower, more stringent criteria for diagnosis identifies patients with glucose intolerance at the most risk of adverse perinatal outcomes.</p><p></p><p class="bulletIndent1">Although the three-hour 100-gram oral GTT is typically performed as the second step of the two-step approach, this is arbitrary and in some countries (eg, Canada) a two-hour 75-gram oral GTT is performed as the second step in the screening/diagnostic process [<a href="#rid84">84</a>]. The procedure and supporting evidence are described below. (See <a class="local">'Procedures and laboratory issues'</a> below and <a class="local">'Validation of the 100-gram GTT'</a> below.)</p><p></p><p class="headingAnchor" id="H1519976767"><span class="h3">Evidence for choosing the two-step versus one-step approach</span><span class="headingEndMark"> — </span>The body of evidence may favor the two-step approach. In a 2022 meta-analysis of randomized trials comparing outcomes of the one- versus the two-step approach:</p><p class="bulletIndent1"><span class="glyph">●</span>The one-step approach diagnosed twice as many patients with GDM (16.3 versus 8.3 percent; RR 2.13, 95% CI 1.61-2.82) and resulted in twice as many patients receiving antihyperglycemic pharmacotherapy (7.1 versus 3.8 percent; RR 2.24, 95% CI 1.21-4.15), without a clear benefit in outcome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most maternal and neonatal outcomes were similar for both groups:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Large for gestational age (LGA; 8.8 versus 9.2 percent; RR 0.95, 95% CI 0.88-1.04)</p><p class="bulletIndent2"><span class="glyph">•</span>Hypertensive disorder of pregnancy (13.6 percent versus 13.6 percent; RR 1.00, 95% CI 0.94-1.07)</p><p class="bulletIndent2"><span class="glyph">•</span>Primary cesarean birth (24.0 versus 24.7 percent; RR 0.98, 95% CI 0.93-1.02)</p><p class="bulletIndent2"><span class="glyph">•</span>Macrosomia (&gt;4000 grams, 11.2 versus 11.3 percent; RR 0.99, 95% CI 0.92-1.07)</p><p class="bulletIndent2"><span class="glyph">•</span>Shoulder dystocia (2.1 versus 2.0 percent; RR 1.06, 95% CI 0.89-1.28)</p><p class="bulletIndent2"><span class="glyph">•</span>Small for gestational age (SGA; 8.6 versus 8.3 percent; RR 1.04, 95% CI 0.95-1.13)</p><p class="bulletIndent2"><span class="glyph">•</span>Stillbirth (0.5 versus 0.6 percent; RR 0.90, 95% CI 0.64-1.28)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal hypoglycemia was more common in the one-step group (9.3 versus 7.6 percent; RR 1.23, 95% CI 1.13-1.34)</p><p></p><p>Results were similar in high-quality observational studies, except for LGA (RR 0.97, 95% CI 0.95-0.98) where the confidence interval was consistent with a modest reduction. </p><p>Based on these findings, it appears that using the one-step method increases the number of patients who receive a diagnosis of GDM and thus has the potential for increased patient and medical system burden (eg, more prenatal visits, fetal and maternal surveillance, lifestyle changes, and intervention) with economic, personal, and psychological consequences [<a href="#rid85">85-87</a>], but without a clear direct benefit over the two-step approach in maternal and newborn outcomes. Therefore, we believe it is prudent to use the two-step approach to diagnose GDM followed by treatment of affected patients according to standard guidelines. Nevertheless, because of limitations of the available trials, the best approach remains controversial [<a href="#rid88">88</a>]. (See <a class="local">'One- and two-step approaches'</a> above.)</p><p>The potential long-term consequences of increasing the number of patients who receive a diagnosis of GDM is another issue. Increased identification of glucose intolerance in pregnancy might lead to improved long-term maternal outcomes. Theoretically, if individuals with GDM are identified and make postpartum lifestyle changes (with or without <a class="drug drug_general" data-topicid="9621" href="/d/drug information/9621.html" rel="external">metformin</a>), this may prevent or delay development of type 2 diabetes later in life [<a href="#rid53">53</a>]. Data are lacking due to the low percentage of patients with GDM who complete the recommended postpartum follow-up. Counseling regarding long-term risk, adherence to a risk-reduction program, and long-term glucose monitoring for diabetes would be essential to assess this issue.</p><p class="headingAnchor" id="H2702890203"><span class="h2">Procedures and laboratory issues</span></p><p class="headingAnchor" id="H696745111"><span class="h3">Screening: 50-gram one-hour GTT</span><span class="headingEndMark"> — </span>A 50-gram oral glucose solution is given without regard to the time elapsed since the last meal/beverage and venous plasma glucose is measured one hour later (sometimes called a glucose challenge test [GCT] or glucose loading test [GLT]). Glucose concentration should be measured using an accurate and precise enzymatic method. The majority of patients (70 to 80 percent) screen negative at this step and thus do not undergo diagnostic testing [<a href="#rid4">4</a>]. </p><p>The following thresholds have been proposed to define a positive screen: ≥130 mg/dL, ≥135 mg/dL, or ≥140 mg/dL (7.2 mmol/L, 7.5 mmol/L, or 7.8 mmol/L). The original threshold for an elevated test (equivalent to 143 mg/dL [7.9 mmol/L] with current methodology) was arbitrary, used whole blood and a nonspecific glucose assay, and was validated by its ability to predict an abnormal 100-gram oral GTT [<a href="#rid89">89</a>]. Using a lower threshold (≥130 mg/dL [7.2 mmol/L] with current methodology) increases sensitivity, but results in more false positives and would require administering a three-hour 100-gram oral GTT to more patients. In a systematic review of cohort studies of screening tests for GDM by the USPSTF, using Carpenter and Coustan criteria, sensitivity and specificity at the ≥130 mg/dL threshold was 100 and 25 percent, respectively, in one study; 90 and 81 percent in a second study; and 75 and 86 percent in a third study [<a href="#rid90">90</a>]. The pooled sensitivity and specificity at ≥135 mg/dL was 93 and 79 percent, respectively; at ≥140 mg/dL pooled sensitivity and specificity were both 82 percent. </p><p>The precise composition of the glucose solution (other than the 50 grams of glucose) can vary among manufactures. No studies have compared products.</p><p class="headingAnchor" id="H2985496671"><span class="h4">Management of patients with results ≥200 mg/dL</span><span class="headingEndMark"> — </span>For patients with one-hour 50-gram glucose concentration ≥200 mg/dL (11.1 mmol/L), the author makes a presumptive diagnosis of GDM, unless the patient prefers to undergo a three-hour 100-gram oral GTT for definitive diagnosis. The GTT can be performed safely, as the 100-gram glucose load would rarely, if ever, lead to a hyperglycemic emergency or other serious adverse events in patients with GDM or unrecognized type 2 diabetes. It has been performed in thousands of patients with no reports of serious adverse events. </p><p>The basis for this approach is that patients who have a very high glucose level on their one-hour 50-gram oral GTT have a high likelihood of an abnormal three-hour 100-gram oral GTT; the positive predictive value (PPV) varies depending on the prevalence of GDM in the population tested and the GTT criteria used for diagnosis. For example, Carpenter and Coustan found that patients whose one-hour 50-gram oral GTT plasma glucose concentration was &gt;182 mg/dL (10.1 mmol/L) had &gt;95 percent probability of an abnormal three-hour 100-gram oral GTT [<a href="#rid4">4</a>]. At glucose levels ≥200 mg/dL (11.1 mmol/L), others have reported PPVs of 47 to 80 percent for an abnormal three-hour 100-gram oral GTT [<a href="#rid83">83,91,92</a>].</p><p class="headingAnchor" id="H3531123331"><span class="h3">Diagnostic testing: 75- and 100-gram GTT</span></p><p class="headingAnchor" id="H3451026680"><span class="h4">Pretest preparation</span><span class="headingEndMark"> — </span>Fasting for 8 to 10 hours is required before the test. Carbohydrate loading for three days before the test is unnecessary if the patient is not on a very-low-carbohydrate diet [<a href="#rid93">93-96</a>]. (See <a class="local">'Options for patients unable to tolerate hyperosmolar oral glucose'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of fasting glucose level</strong> – A fasting glucose level is rarely determined before administering the GTT. This approach would require asking the patient to have blood drawn for their fasting glucose level and then wait for the results before going ahead with the GTT later the same day (and remain fasting) or on another day (and fasting again), which is cumbersome. Excluding fasting hyperglycemia before a GTT is unnecessary to safely perform the test. However, identifying fasting hyperglycemia can reduce testing for some patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a 75-gram oral GTT is planned and the fasting glucose level is ≥92 mg/dL (5.1 mmol/L), then the diagnosis of GDM is made and the GTT is cancelled. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If a 100-gram oral GTT is planned, no data support a particular fasting cutoff for diagnosing GDM and an abnormal fasting glucose level alone is not diagnostic of GDM. However, a glucose level ≥126 mg/dL (7 mmol/L) is a reasonable threshold for cancelling the GTT as it is diagnostic of diabetes in the general population.</p><p></p><p class="headingAnchor" id="H453608051"><span class="h4">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of GDM is based on plasma glucose values during the two-hour GTT using a 75-gram oral glucose load or during the three-hour GTT using a 100-gram oral glucose load. Thresholds for a positive test are shown in the tables  (<a class="graphic graphic_table graphicRef80677 graphicRef61208" href="/d/graphic/80677.html" rel="external">table 3B-C</a>).</p><p>The GTT is an imprecise test with poor reproducibility [<a href="#rid97">97</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a study that performed two 100-gram oral GTTs one to two weeks apart in 64 pregnant people whose one-hour 50-gram oral GTT was ≥135 mg/dL, 48 had normal/normal, 11 had normal/abnormal, three had abnormal/normal, and two had abnormal/abnormal results [<a href="#rid98">98</a>]. Thus, only 50 of 64 (78 percent) had reproducible test results. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a trial that performed a two-hour 75-gram oral GTT before 20 weeks and repeated the test at 24 to 28 weeks, one-third of participants had abnormal followed by normal results [<a href="#rid76">76</a>]. </p><p></p><p>Nevertheless, the 100-gram oral GTT is a practical and widely utilized means of diagnosing GDM, and the 75-gram oral GTT is a widely utilized means of diagnosing diabetes in both pregnant and nonpregnant individuals. Proper handling and processing of blood samples are important for accurate results [<a href="#rid99">99</a>].</p><p class="headingAnchor" id="H560522473"><span class="h4">Options for patients unable to tolerate hyperosmolar oral glucose</span><span class="headingEndMark"> — </span>The highly concentrated hyperosmolar glucose solution used for the GTT can cause gastric irritation, delayed emptying, and gastrointestinal osmotic imbalance, leading to nausea and, in a small percentage of patients, vomiting [<a href="#rid100">100-102</a>]. Options in these cases include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serving over ice</strong> – Serving the hyperosmolar glucose drink on ice may reduce nausea and vomiting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiemetic premedication</strong> – If the patient vomited during the oral GTT and is willing to come back another day for repeat testing, premedication with an antiemetic drug may allow the test to be completed. In one study, 8 percent of patients could not complete the 100-gram oral GTT because of vomiting [<a href="#rid100">100</a>]. It is possible that fewer patients vomit with the 75-gram oral GTT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous GTT</strong> – The GTT can be performed intravenously instead of orally, although this is rarely done because it is onerous, expensive, and unvalidated in pregnancy [<a href="#rid103">103</a>]. Considering these limitations, we recommend not using it.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Structured postprandial glucose assessment</strong> – Periodic fasting and one- or two-hour postprandial blood glucose tests can be obtained in pregnant people at high risk for GDM. For example, they can be asked to keep a weekly log of self-monitored glucose values from 24 to 28 weeks (the gestational age when screening would be performed) and at 32 weeks (the gestational age of peak insulin resistance).</p><p></p><p class="bulletIndent1">This approach is also useful for pregnant people who have dumping syndrome after a Roux-en-Y gastric bypass procedure; these individuals are unlikely to tolerate a hyperosmolar glucose solution [<a href="#rid104">104</a>]. Monitoring glucose values will only identify those cases of GDM that might require intervention for hyperglycemia and not all cases of GDM. (See  <a class="medical medical_review" href="/d/html/411.html" rel="external">"Fertility and pregnancy after bariatric surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Other approaches have been tried in patients who do not tolerate or decline to have an oral GTT, but are not recommended because they have not been validated or they perform poorly.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Candy, a predefined meal, or commercial soft drinks with 75 or 100 grams of glucose have been used instead of a standard glucose monomer or polymer solution [<a href="#rid105">105-110</a>]. These oral glucose loads are better tolerated but appear to be less sensitive and have not been validated in large studies. None have been endorsed by the ADA or ACOG.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A1C – In a USPSTF systematic review, no threshold for glycated hemoglobin (A1C) in the second and third trimesters had both good sensitivity and specificity as a screening test for GDM [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fasting glucose alone – The USPSTF review also found that a fasting plasma glucose threshold of 79 mg/dL was required to achieve high (96 percent) sensitivity but specificity was poor (35 percent) [<a href="#rid90">90</a>]. A fasting plasma glucose threshold of 95.5 mg/dL was required to achieve high specificity (98 percent) but sensitivity was 58 percent at this level. </p><p></p><p class="bulletIndent2">However, in low-resource settings where universal screening with a GTT is not feasible, use of fasting plasma glucose at 24 to 28 weeks to screen pregnant people may be a practical approach, a reasonable trade-off between cost savings and adverse outcomes in missed cases. In a study from 15 Chinese hospitals, if performance of the GTT was restricted to pregnant people with fasting glucose from 79 mg/dL (4.4 mmol/L) to 90 mg/dL (5.0 mmol/L), then 50 percent of pregnant people could avoid a GTT since 38 percent of this population had fasting glucose &lt;79 mg/dL (4.4 mmol/L) and 12 percent had fasting glucose &gt;90 mg/dL (5.0 mmol/L), diagnostic of GDM in this system; 12 percent of patients with GDM were missed [<a href="#rid111">111</a>]. These findings may not be generalizable to other low-resource populations since Asian females have a higher incidence of type 2 diabetes and GDM than White females, and fasting hyperglycemia among Asian females with GDM is less prominent than in non-Asian populations [<a href="#rid112">112</a>]. In non-Asian populations, 50 to 75 percent of patients with GDM have fasting glucose levels ≥92 mg/dL (5.1 mmol/L) on an oral GTT [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Testing for glucosuria – A positive urine dipstick for glycosuria is not very predictive of GDM, and a negative urine dipstick for glycosuria is not very predictive of absence of GDM, so should not be used for ruling the diagnosis in or out [<a href="#rid113">113-115</a>]. Glycosuria with a normal blood glucose level is common in pregnant people as pregnancy is associated with reductions in fractional reabsorption of glucose, which results in higher rates of urinary excretion.</p><p></p><p class="headingAnchor" id="H5480965"><span class="h4">Validation of the 100-gram GTT</span><span class="headingEndMark"> — </span>The three-hour 100-gram oral GTT is diagnostic of GDM when two glucose values are elevated. The most commonly used thresholds for defining elevated values were proposed by Carpenter and Coustan  (<a class="graphic graphic_table graphicRef80677" href="/d/graphic/80677.html" rel="external">table 3B</a>) [<a href="#rid4">4</a>], which is a modification of thresholds proposed by O’Sullivan and Mahan [<a href="#rid116">116</a>], originally based on venous whole blood samples. The Carpenter and Coustan values are based on newer enzymatic assays performed on plasma samples and reflect current laboratory practices.</p><p>The requirement for two abnormal values on the GTT was an arbitrary decision made by O’Sullivan and Mahan in 1964 [<a href="#rid116">116</a>]. Treatment of patients who meet these diagnostic criteria for GDM improves some pregnancy outcomes (eg, pregnancy-induced hypertension, macrosomia, shoulder dystocia) [<a href="#rid117">117</a>]. However, a 2016 systematic review including 25 studies noted that pregnant people with one abnormal value on the 100-gram oral GTT generally had increased risks for the same poor outcomes as those with two abnormal values (ie, GDM) [<a href="#rid118">118</a>]. This subset of patients may warrant closer monitoring for fetal overgrowth and other adverse outcomes of GDM, as well as closer monitoring for future development of type 2 diabetes [<a href="#rid119">119</a>]. Whether they would benefit from treatment is unknown. The author of this topic obtains a third-trimester fetal growth scan on these patients. If fetal overgrowth or polyhydramnios is present, she discusses the option of home glucose monitoring. </p><p class="headingAnchor" id="H5480972"><span class="h4">Validation of the 75-gram GTT</span><span class="headingEndMark"> — </span>The two-hour 75-gram oral GTT is diagnostic of GDM when one glucose value is elevated. The most commonly used thresholds for defining elevated values have been proposed by the IADPSG  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>). The 75-gram oral GTT is generally more sensitive for identifying the pregnancy at risk for adverse outcome (eg, gestational hypertension, preeclampsia, LGA) than the 100-gram oral GTT [<a href="#rid120">120</a>]. Increased sensitivity is primarily related to the need for only one elevated glucose value for a positive test [<a href="#rid112">112</a>], as well as slightly lower glucose thresholds. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study</strong> – The IADPSG-defined thresholds for the 75-gram oral GTT are primarily based on outcome data reported in the HAPO study, a prospective observational study of more than 23,000 pregnancies in nine countries evaluated with a 75-gram oral GTT at 24 to 32 weeks of gestation [<a href="#rid7">7,19</a>]. These thresholds represent the glucose values at which the odds of neonatal birth weight, cord C-peptide (surrogate for fetal insulin level), and percent body fat &gt;90<sup>th</sup> percentile were 1.75 times the estimated odds of these outcomes at mean glucose levels, based on fully adjusted logistic regression models. Compared with participants in the HAPO study with all glucose values below the thresholds, those who exceeded one or more of these thresholds had a twofold higher frequency of LGA newborns and preeclampsia and &gt;45 percent increase in preterm birth and primary cesarean birth. Using an odds ratio (OR) of 2 for the thresholds defined a population with a higher frequency of these outcomes, but the difference was modest and resulted in failure to identify many pregnant people who were at almost similar risk of these outcomes but had all glucose values below the thresholds. IADPSG-defined thresholds are also predictive of a more than threefold increased long-term risk of diabetes and metabolic syndrome [<a href="#rid121">121,122</a>]. In a post hoc analysis of data from the HAPO Study, 52 percent of pregnant people who would meet IADPSG criteria for GDM developed a disorder of glucose metabolism by 10 to 14 years postpartum, compared with 20 percent of those without GDM (OR 3.44, 95% CI 2.85-4.14 [<a href="#rid122">122</a>]). Among pregnant people who met IADPSG criteria for GDM, rates of type 2 diabetes and prediabetes were 10.7 and 41.5 percent, respectively, versus rates of 1.6 and 18.4 percent, respectively, in those without GDM. The children of these individuals were more likely to be “overweight or obese” (39.5 versus 28.6 percent in children of mothers without GDM, OR 1.21, 95% CI 1.00-1.46) after adjustment for maternal body mass index (BMI) during pregnancy, and the difference in prevalence of obesity was statistically significant (19 versus 10 percent in children of mothers without GDM, OR 1.58, 95% CI 1.24-2.01).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-HAPO</strong> <strong>data</strong> – In 2022, the IADPSG-defined thresholds for the 75-gram oral GTT were reassessed in a trial that randomly assigned 4061 pregnant patients undergoing GDM screening to the standard glycemic threshold criteria for diagnosis  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>) or higher thresholds (ie, fasting plasma glucose ≥99 mg/dL [≥5.5 mmol/L] or two-hour glucose ≥162 mg/dL [≥9.0 mmol/L]) [<a href="#rid123">123</a>]. Patients who met the threshold criteria for GDM for their assigned group received usual care for patients with GDM (per New Zealand Ministry of Health clinical practice guideline on GDM). Major findings were:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of lower glycemic threshold criteria resulted in more patients diagnosed with GDM (15.3 versus 6.1 percent), but this was not accompanied by a significant reduction in birth of LGA (8.8 versus 8.9 percent) or macrosomic newborns (11.8 versus 12.3 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of the lower glycemic threshold criteria resulted in more inductions of labor (33.7 versus 30.2 percent), use of health services, and use of pharmacotherapy (10.9 versus 4.6 percent). The lower glycemic threshold group also had a higher rate of neonatal hypoglycemia warranting treatment (10.7 versus 8.4 percent), which was likely related to hospital protocols requiring screening for hypoglycemia in infants of diabetic mothers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rates of preeclampsia, preterm birth, shoulder dystocia, cesarean birth, and SGA newborn were similar in the two trial groups.</p><p></p><p class="bulletIndent1">Interestingly, about half of the patients with glucose test results that fell between the lower and higher glycemic threshold criteria were considered by their providers to have a mild degree of GDM and were treated for GDM. These patients had maternal and infant health benefits, including fewer LGA newborns, compared with those who did not receive a diagnosis of a mild degree of GDM and therefore not treated.</p><p></p><p class="bulletIndent1">The results of this trial suggest that the optimum glucose thresholds for diagnosis of GDM by the 75-gram oral GTT still need to be determined.</p><p></p><p class="headingAnchor" id="H4144980330"><span class="h1">SHOULD TESTING BE REPEATED LATER IN PREGNANCY?</span><span class="headingEndMark"> — </span>We recommend not repeating a glucose tolerance test (GTT) later in pregnancy after an initially normal GTT. Although some studies have reported that repeating the test after an initially normal GTT (defined as the absence of at least two glucose values above threshold) will identify additional cases in 4 to 29 percent of cases depending on the timing and indication for repeat testing [<a href="#rid124">124-127</a>], the value of identifying these individuals versus nondiagnosis of GDM is unproven. Furthermore, patients with a normal GTT and sonographic signs of fetal overgrowth or with one abnormal value on the GTT can be given the option of insulin therapy in an attempt to improve pregnancy outcome. </p><p class="headingAnchor" id="H1342274197"><span class="h1">RECOMMENDATIONS OF NATIONAL AND INTERNATIONAL ORGANIZATIONS</span><span class="headingEndMark"> — </span>The optimum strategy for diagnosis of GDM to improve maternal and infant health is unclear [<a href="#rid128">128</a>]. Many organizations have published recommendations for screening and diagnosis of diabetes in pregnancy:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2F&amp;token=IQxLzDq4doJGUgaZgeIY0zxFSMEuWanwNDC0bEdrSRs%3D&amp;TOPIC_ID=6797" target="_blank">American College of Obstetricians and Gynecologists</a> (ACOG, two-step approach  (<a class="graphic graphic_table graphicRef78433" href="/d/graphic/78433.html" rel="external">table 3A</a> and <a class="graphic graphic_table graphicRef80677" href="/d/graphic/80677.html" rel="external">table 3B</a>)) [<a href="#rid3">3</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcare.diabetesjournals.org%2Fcontent%2F33%2F3%2F676&amp;token=85UBP6D7FNYac5zdqfjecWZWoNOf2%2FAIxo7RmnXYNNxBTS15cVw4P535mcjX8mD4lGoBmmoB%2BCUZxj3ej6ZKrw%3D%3D&amp;TOPIC_ID=6797" target="_blank">International Association of Diabetes and Pregnancy Study Groups</a> (IADPSG, one-step approach  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>)) [<a href="#rid7">7</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fcare.diabetesjournals.org%2Fcontent%2F37%2FSupplement_1%2FS14&amp;token=85UBP6D7FNYac5zdqfjecWZWoNOf2%2FAIxo7RmnXYNNx853tZ60do2PD2lvfd%2FSEieRuHGZD1FRocvVv9NMMBgDLL9g6H29RVL3AF4unoWNg%3D&amp;TOPIC_ID=6797" target="_blank">American Diabetes Association</a> (ADA, one- or two-step approach) [<a href="#rid2">2</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2FWHO-RHR-16.12&amp;token=mr3MkQMxxRm373pPGLTYB%2B8L7rJeOJtqYOfpSLq18h72TpzHNiPAL1p0MBMxoloxeN8XzjbqanV4R437X1euAQ%3D%3D&amp;TOPIC_ID=6797" target="_blank">World Health Organization</a> (WHO, one-step approach  (<a class="graphic graphic_table graphicRef93396" href="/d/graphic/93396.html" rel="external">table 4</a>)) [<a href="#rid129">129</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fguidelines.diabetes.ca%2Fcpg%2Fchapter36&amp;token=tkePy2Easa%2BvweiDgA97J4VlZ8gqMZZ%2Fg6WQUncOyQvZbVs5FlOINS5aL53SibjFrK3rVxhnIWjpTfoYiwWM5A%3D%3D&amp;TOPIC_ID=6797" target="_blank">Canadian Diabetes Association</a> (CDA, two-step [preferred] or one-step approach) [<a href="#rid84">84</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.adips.org%2F&amp;token=pA%2FJFTzFzVWnmq81WzE5RSUUI9RovCK0qLTKVXC%2Fyt0%3D&amp;TOPIC_ID=6797" target="_blank">Australasian Diabetes in Pregnancy Society</a> (WHO approach) [<a href="#rid41">41</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.nice.org.uk%2Fguidance%2Fng3%2Fchapter%2F1-recommendations&amp;token=ufKeAHJx6iF9gKdHYTlHMISyenJ0BYiDjjlkxmn2rXMXqs3yJN%2FY2VEtZ4dXPyYMI%2FG3p9FQjfhRG0ql7hcWjpEGD60IgacLqkjWEaKgdGY%3D&amp;TOPIC_ID=6797" target="_blank">National Institute for Health and Care Excellence</a> (NICE, United Kingdom, one-step approach)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>International Federation of Gynecology and Obstetrics (FIGO, one-step approach) [<a href="#rid130">130</a>]</p><p></p><p class="headingAnchor" id="H287012471"><span class="h1">POSTDELIVERY FOLLOW-UP</span><span class="headingEndMark"> — </span>Although pregnancy-related maternal insulin resistance returns to prepregnancy levels within a few days of giving birth, individuals with GDM should be screened again 4 to 12 weeks postpartum and periodically (at least every three years) thereafter because they are at increased risk for developing type 2 diabetes mellitus. Postdelivery follow-up is described separately. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Follow-up'</a>.)</p><p class="headingAnchor" id="H69781273"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109438.html" rel="external">"Society guideline links: Diabetes mellitus in pregnancy"</a>.)</p><p class="headingAnchor" id="H2694488169"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15435.html" rel="external">"Patient education: Gestational diabetes (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/6735.html" rel="external">"Patient education: Gestational diabetes (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H23"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Terminology and significance</strong> – Gestational diabetes mellitus (GDM) typically refers to diagnosis of diabetes at 24 to 28 weeks of gestation. Diagnosis of diabetes early in pregnancy (sometimes called overt diabetes) is more consistent with previously undiagnosed type 2 diabetes. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1">GDM has been associated with increased risks of several adverse outcomes  (<a class="graphic graphic_table graphicRef140918" href="/d/graphic/140918.html" rel="external">table 5</a>). The association between hyperglycemia and adverse pregnancy outcomes is dose-dependent and continuous. (See <a class="local">'Significance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>How to screen</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Overall approach</strong> – An overall approach to screening for diabetes in pregnancy and after delivery is shown in the algorithm  (<a class="graphic graphic_algorithm graphicRef129328" href="/d/graphic/129328.html" rel="external">algorithm 1</a>). (See <a class="local">'Screening for overt diabetes in early pregnancy'</a> above and <a class="local">'Screening for GDM at 24 to 28 weeks'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Early pregnancy screening for previously undiagnosed type 2 diabetes</strong> – There is no standard approach to early pregnancy screening for undiagnosed type 2 diabetes. The author obtains an A1C level at the initial prenatal visit in all patients as part of the initial prenatal blood work; a value ≥6.5 percent (≥48 mmol/mol) is diagnostic of diabetes and the patient is managed accordingly. If the A1C is &lt;6.5 percent (&lt;48 mmol/mol), the author performs standard screening for GDM at 24 to 28 weeks. Alternatively, several national organizations have suggested a targeted approach that limits screening to patients at high risk. (See <a class="local">'Screening for overt diabetes in early pregnancy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Screening for GDM at 24 to 28 weeks</strong> – We suggest screening for GDM at 24 to 28 weeks of gestation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In the United States, universal rather than selective screening appears to be the most practical approach because 90 percent of pregnant people have at least one risk factor for glucose impairment during pregnancy and 20 percent of individuals with GDM have no risk factors. In pregnant people with GDM, treatment (medical nutritional therapy, and then pharmacotherapy if glycemic goals are not achieved) can reduce the rate of some adverse pregnancy outcomes, particularly macrosomia and shoulder dystocia, and possibly preeclampsia. (See <a class="local">'Candidates'</a> above and <a class="local">'Significance'</a> above and <a class="local">'Benefits and harms of screening'</a> above and  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Rationale for treatment'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>One- and two-step testing approaches</strong> – We use a two-step approach for screening/diagnosis of GDM  (<a class="graphic graphic_table graphicRef78433 graphicRef80677" href="/d/graphic/78433.html" rel="external">table 3A-B</a>), but a one-step approach is also acceptable  (<a class="graphic graphic_table graphicRef61208" href="/d/graphic/61208.html" rel="external">table 3C</a>). (See <a class="local">'One- and two-step approaches'</a> above and <a class="local">'Procedures and laboratory issues'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postpartum follow-up</strong> – Individuals with GDM should be screened for diabetes postpartum and periodically thereafter because they are at increased risk for developing type 2 diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/6790.html" rel="external">"Gestational diabetes mellitus: Glucose management and maternal prognosis", section on 'Follow-up'</a>.)</p><p></p><p class="headingAnchor" id="H4061344357"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Lois Jovanovic, MD, Donald R Coustan, MD, and Michael Greene, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes Care 1998; 21 Suppl 2:B1.</a></li><li><a class="nounderline abstract_t">American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care 2024; 47:S20.</a></li><li><a class="nounderline abstract_t">ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol 2018; 131:e49.</a></li><li><a class="nounderline abstract_t">Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144:768.</a></li><li><a class="nounderline abstract_t">Gregory EC, Ely DM. Trends and Characteristics in Gestational Diabetes: United States, 2016-2020. Natl Vital Stat Rep 2022; 71:1.</a></li><li><a class="nounderline abstract_t">Bilous RW, Jacklin PB, Maresh MJ, Sacks DA. Resolving the Gestational Diabetes Diagnosis Conundrum: The Need for a Randomized Controlled Trial of Treatment. Diabetes Care 2021; 44:858.</a></li><li><a class="nounderline abstract_t">International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33:676.</a></li><li><a class="nounderline abstract_t">Guariguata L, Linnenkamp U, Beagley J, et al. Global estimates of the prevalence of hyperglycaemia in pregnancy. Diabetes Res Clin Pract 2014; 103:176.</a></li><li><a class="nounderline abstract_t">Getahun D, Nath C, Ananth CV, et al. Gestational diabetes in the United States: temporal trends 1989 through 2004. Am J Obstet Gynecol 2008; 198:525.e1.</a></li><li><a class="nounderline abstract_t">Albrecht SS, Kuklina EV, Bansil P, et al. Diabetes trends among delivery hospitalizations in the U.S., 1994-2004. Diabetes Care 2010; 33:768.</a></li><li><a class="nounderline abstract_t">Kim SY, Saraiva C, Curtis M, et al. Fraction of gestational diabetes mellitus attributable to overweight and obesity by race/ethnicity, California, 2007-2009. Am J Public Health 2013; 103:e65.</a></li><li><a class="nounderline abstract_t">Feig DS, Hwee J, Shah BR, et al. Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996-2010. Diabetes Care 2014; 37:1590.</a></li><li><a class="nounderline abstract_t">Abouzeid M, Versace VL, Janus ED, et al. A population-based observational study of diabetes during pregnancy in Victoria, Australia, 1999-2008. BMJ Open 2014; 4:e005394.</a></li><li><a class="nounderline abstract_t">Shah NS, Wang MC, Freaney PM, et al. Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011-2019. JAMA 2021; 326:660.</a></li><li><a class="nounderline abstract_t">Venkatesh KK, Harrington K, Cameron NA, et al. Trends in gestational diabetes mellitus among nulliparous pregnant individuals with singleton live births in the United States between 2011 to 2019: an age-period-cohort analysis. Am J Obstet Gynecol MFM 2023; 5:100785.</a></li><li><a class="nounderline abstract_t">Nethery E, Law MR, Kotaska A, et al. The effect of changing screening practices and demographics on the incidence of gestational diabetes in British Columbia, 2005-2019. CMAJ 2023; 195:E396.</a></li><li><a class="nounderline abstract_t">Venkatesh KK, Lynch CD, Powe CE, et al. Risk of Adverse Pregnancy Outcomes Among Pregnant Individuals With Gestational Diabetes by Race and Ethnicity in the United States, 2014-2020. JAMA 2022; 327:1356.</a></li><li><a class="nounderline abstract_t">Ye W, Luo C, Huang J, et al. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. BMJ 2022; 377:e067946.</a></li><li><a class="nounderline abstract_t">HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358:1991.</a></li><li><a class="nounderline abstract_t">Landon MB, Mele L, Spong CY, et al. The relationship between maternal glycemia and perinatal outcome. Obstet Gynecol 2011; 117:218.</a></li><li><a class="nounderline abstract_t">Farrar D, Simmonds M, Bryant M, et al. Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis. BMJ 2016; 354:i4694.</a></li><li><a class="nounderline abstract_t">Maya J, Selen DJ, Thaweethai T, et al. Gestational Glucose Intolerance and Birth Weight-Related Complications. Obstet Gynecol 2023; 142:594.</a></li><li><a class="nounderline abstract_t">Zhang TN, Huang XM, Zhao XY, et al. Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births. PLoS Med 2022; 19:e1003900.</a></li><li><a class="nounderline abstract_t">Parnell AS, Correa A, Reece EA. Pre-pregnancy Obesity as a Modifier of Gestational Diabetes and Birth Defects Associations: A Systematic Review. Matern Child Health J 2017; 21:1105.</a></li><li><a class="nounderline abstract_t">Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009; 301:636.</a></li><li><a class="nounderline abstract_t">Xiang AH, Wang X, Martinez MP, et al. Association of maternal diabetes with autism in offspring. JAMA 2015; 313:1425.</a></li><li><a class="nounderline abstract_t">Li M, Fallin MD, Riley A, et al. The Association of Maternal Obesity and Diabetes With Autism and Other Developmental Disabilities. Pediatrics 2016; 137:e20152206.</a></li><li><a class="nounderline abstract_t">Xu G, Jing J, Bowers K, et al. Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis. J Autism Dev Disord 2014; 44:766.</a></li><li><a class="nounderline abstract_t">Ornoy A, Reece EA, Pavlinkova G, et al. Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes. Birth Defects Res C Embryo Today 2015; 105:53.</a></li><li><a class="nounderline abstract_t">Lowe WL Jr, Scholtens DM, Kuang A, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism. Diabetes Care 2019; 42:372.</a></li><li><a class="nounderline abstract_t">Scholtens DM, Kuang A, Lowe LP, et al. Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Glycemia and Childhood Glucose Metabolism. Diabetes Care 2019; 42:381.</a></li><li><a class="nounderline abstract_t">Solomon CG, Willett WC, Carey VJ, et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 1997; 278:1078.</a></li><li><a class="nounderline abstract_t">Kiani F, Naz MS, et al. The Risk Factors of Gestational Diabetes Mellitus: A. Int J Womens Health 2017; 5:253.</a></li><li><a class="nounderline abstract_t">Kim C, Liu T, Valdez R, Beckles GL. Does frank diabetes in first-degree relatives of a pregnant woman affect the likelihood of her developing gestational diabetes mellitus or nongestational diabetes? Am J Obstet Gynecol 2009; 201:576.e1.</a></li><li><a class="nounderline abstract_t">Hedderson MM, Williams MA, Holt VL, et al. Body mass index and weight gain prior to pregnancy and risk of gestational diabetes mellitus. Am J Obstet Gynecol 2008; 198:409.e1.</a></li><li><a class="nounderline abstract_t">Hedderson MM, Gunderson EP, Ferrara A. Gestational weight gain and risk of gestational diabetes mellitus. Obstet Gynecol 2010; 115:597.</a></li><li><a class="nounderline abstract_t">Gibson KS, Waters TP, Catalano PM. Maternal weight gain in women who develop gestational diabetes mellitus. Obstet Gynecol 2012; 119:560.</a></li><li><a class="nounderline abstract_t">Carreno CA, Clifton RG, Hauth JC, et al. Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous women. Obstet Gynecol 2012; 119:1227.</a></li><li><a class="nounderline abstract_t">Miller C, Lim E. The risk of diabetes after giving birth to a macrosomic infant: data from the NHANES cohort. Matern Health Neonatol Perinatol 2021; 7:12.</a></li><li><a class="nounderline abstract_t">Getahun D, Fassett MJ, Jacobsen SJ. Gestational diabetes: risk of recurrence in subsequent pregnancies. Am J Obstet Gynecol 2010; 203:467.e1.</a></li><li><a class="nounderline abstract_t">Hartling L, Dryden DM, Guthrie A, et al. Screening and diagnosing gestational diabetes mellitus. Evid Rep Technol Assess (Full Rep) 2012; :1.</a></li><li><a class="nounderline abstract_t">Danilenko-Dixon DR, Van Winter JT, Nelson RL, Ogburn PL Jr. Universal versus selective gestational diabetes screening: application of 1997 American Diabetes Association recommendations. Am J Obstet Gynecol 1999; 181:798.</a></li><li><a class="nounderline abstract_t">Guo XY, Shu J, Fu XH, et al. Improving the effectiveness of lifestyle interventions for gestational diabetes prevention: a meta-analysis and meta-regression. BJOG 2019; 126:311.</a></li><li><a class="nounderline abstract_t">Burke AE, Bennett WL, Jamshidi RM, et al. Reduced incidence of gestational diabetes with bariatric surgery. J Am Coll Surg 2010; 211:169.</a></li><li><a class="nounderline abstract_t">Magro-Malosso ER, Saccone G, Di Mascio D, et al. Exercise during pregnancy and risk of preterm birth in overweight and obese women: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand 2017; 96:263.</a></li><li><a class="nounderline abstract_t">Russo LM, Nobles C, Ertel KA, et al. Physical activity interventions in pregnancy and risk of gestational diabetes mellitus: a systematic review and meta-analysis. Obstet Gynecol 2015; 125:576.</a></li><li><a class="nounderline abstract_t">Sanabria-Martínez G, García-Hermoso A, Poyatos-León R, et al. Effectiveness of physical activity interventions on preventing gestational diabetes mellitus and excessive maternal weight gain: a meta-analysis. BJOG 2015; 122:1167.</a></li><li><a class="nounderline abstract_t">Martínez-Vizcaíno V, Sanabria-Martínez G, Fernández-Rodríguez R, et al. Exercise during pregnancy for preventing gestational diabetes mellitus and hypertensive disorders: An umbrella review of randomised controlled trials and an updated meta-analysis. BJOG 2023; 130:264.</a></li><li><a class="nounderline abstract_t">Rogozińska E, Chamillard M, Hitman GA, et al. Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies. PLoS One 2015; 10:e0115526.</a></li><li><a class="nounderline abstract_t">Schoenaker DA, Mishra GD, Callaway LK, Soedamah-Muthu SS. The Role of Energy, Nutrients, Foods, and Dietary Patterns in the Development of Gestational Diabetes Mellitus: A Systematic Review of Observational Studies. Diabetes Care 2016; 39:16.</a></li><li><a class="nounderline abstract_t">Tieu J, Shepherd E, Middleton P, Crowther CA. Dietary advice interventions in pregnancy for preventing gestational diabetes mellitus. Cochrane Database Syst Rev 2017; 1:CD006674.</a></li><li><a class="nounderline abstract_t">Terry PD, Weiderpass E, Ostenson CG, Cnattingius S. Cigarette smoking and the risk of gestational and pregestational diabetes in two consecutive pregnancies. Diabetes Care 2003; 26:2994.</a></li><li><a class="nounderline abstract_t">Aroda VR, Christophi CA, Edelstein SL, et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up. J Clin Endocrinol Metab 2015; 100:1646.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77:520.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Pranikoff J, Aregawi D, Wang P. Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertil Steril 2008; 89:625.</a></li><li><a class="nounderline abstract_t">Vanky E, Stridsklev S, Heimstad R, et al. Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. J Clin Endocrinol Metab 2010; 95:E448.</a></li><li><a class="nounderline abstract_t">Syngelaki A, Nicolaides KH, Balani J, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med 2016; 374:434.</a></li><li><a class="nounderline abstract_t">Chiswick C, Reynolds RM, Denison F, et al. Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2015; 3:778.</a></li><li><a class="nounderline abstract_t">Davidson SJ, Barrett HL, Price SA, et al. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev 2021; 4:CD009951.</a></li><li><a class="nounderline abstract_t">Motuhifonua SK, Lin L, Alsweiler J, et al. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev 2023; 2:CD011507.</a></li><li><a class="nounderline abstract_t">US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:531.</a></li><li><a class="nounderline abstract_t">Pillay J, Donovan L, Guitard S, et al. Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021; 326:539.</a></li><li><a class="nounderline abstract_t">Hivert MF, Allard C, Menard J, et al. Impact of the creation of a specialized clinic for prenatal blood sampling and follow-up care in pregnant women. J Obstet Gynaecol Can 2012; 34:236.</a></li><li><a class="nounderline abstract_t">Stacey T, Tennant P, McCowan L, et al. Gestational diabetes and the risk of late stillbirth: a case-control study from England, UK. BJOG 2019; 126:973.</a></li><li><a class="nounderline abstract_t">Lohse N, Marseille E, Kahn JG. Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus. Int J Gynaecol Obstet 2011; 115 Suppl 1:S20.</a></li><li><a class="nounderline abstract_t">Farrar D, Simmonds M, Griffin S, et al. The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation. Health Technol Assess 2016; 20:1.</a></li><li><a class="nounderline abstract_t">Beilby H, Yang F, Gannon B, McIntyre HD. Cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of the GeDiForCE model in Australia. J Matern Fetal Neonatal Med 2022; 35:8286.</a></li><li><a class="nounderline abstract_t">Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care 2010; 33:562.</a></li><li><a class="nounderline abstract_t">McIntyre HD. Discovery, Knowledge, and Action-Diabetes in Pregnancy Across the Translational Spectrum: The 2016 Norbert Freinkel Award Lecture. Diabetes Care 2018; 41:227.</a></li><li><a class="nounderline abstract_t">Schaefer UM, Songster G, Xiang A, et al. Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy. Am J Obstet Gynecol 1997; 177:1165.</a></li><li><a class="nounderline abstract_t">Omori Y, Jovanovic L. Proposal for the reconsideration of the definition of gestational diabetes. Diabetes Care 2005; 28:2592.</a></li><li><a class="nounderline abstract_t">Sheffield JS, Butler-Koster EL, Casey BM, et al. Maternal diabetes mellitus and infant malformations. Obstet Gynecol 2002; 100:925.</a></li><li><a class="nounderline abstract_t">McLaren RA Jr, Ruymann KR, Ramos GA, et al. Early screening for gestational diabetes mellitus: a meta-analysis of randomized controlled trials. Am J Obstet Gynecol MFM 2022; 4:100737.</a></li><li><a class="nounderline abstract_t">Radder JK, van Roosmalen J. HbA1c in healthy, pregnant women. Neth J Med 2005; 63:256.</a></li><li><a class="nounderline abstract_t">Fong A, Serra AE, Gabby L, et al. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. Am J Obstet Gynecol 2014; 211:641.e1.</a></li><li><a class="nounderline abstract_t">Simmons D, Immanuel J, Hague WM, et al. Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. N Engl J Med 2023; 388:2132.</a></li><li><a class="nounderline abstract_t">Harper LM, Jauk V, Longo S, et al. Early gestational diabetes screening in obese women: a randomized controlled trial. Am J Obstet Gynecol 2020; 222:495.e1.</a></li><li><a class="nounderline abstract_t">Bhattacharya SM. Glucose screening test results in first and early third trimester of pregnancy: is there any correlation? J Obstet Gynaecol Res 2002; 28:304.</a></li><li><a class="nounderline abstract_t">Nahum GG, Huffaker BJ. Correlation between first- and early third-trimester glucose screening test results. Obstet Gynecol 1990; 76:709.</a></li><li><a class="nounderline abstract_t">Avalos GE, Owens LA, Dunne F, ATLANTIC DIP Collaborators. Applying current screening tools for gestational diabetes mellitus to a European population: is it time for change? Diabetes Care 2013; 36:3040.</a></li><li><a class="nounderline abstract_t">Chevalier N, Fénichel P, Giaume V, et al. Universal two-step screening strategy for gestational diabetes has weak relevance in French Mediterranean women: should we simplify the screening strategy for gestational diabetes in France? Diabetes Metab 2011; 37:419.</a></li><li><a class="nounderline abstract_t">Farrar D, Simmonds M, Bryant M, et al. Risk factor screening to identify women requiring oral glucose tolerance testing to diagnose gestational diabetes: A systematic review and meta-analysis and analysis of two pregnancy cohorts. PLoS One 2017; 12:e0175288.</a></li><li><a class="nounderline abstract_t">Temming LA, Tuuli MG, Stout MJ, et al. Diagnostic ability of elevated 1-h glucose challenge test. J Perinatol 2016; 36:342.</a></li><li><a class="nounderline abstract_t">Thompson D, Berger H, Feig D, et al. Diabetes and pregnancy. Can J Diabetes 2013; 37:S1.</a></li><li><a class="nounderline abstract_t">Marchetti D, Carrozzino D, Fraticelli F, et al. Quality of Life in Women with Gestational Diabetes Mellitus: A Systematic Review. J Diabetes Res 2017; 2017:7058082.</a></li><li><a class="nounderline abstract_t">Craig L, Sims R, Glasziou P, Thomas R. Women's experiences of a diagnosis of gestational diabetes mellitus: a systematic review. BMC Pregnancy Childbirth 2020; 20:76.</a></li><li><a class="nounderline abstract_t">Ludgin J, Werner E. More Is Not Always Better. Obstet Gynecol 2022; 140:710.</a></li><li><a class="nounderline abstract_t">Coustan DR, Dyer AR, Metzger BE. One-step or 2-step testing for gestational diabetes: which is better? Am J Obstet Gynecol 2021; 225:634.</a></li><li><a class="nounderline abstract_t">O'Sullivan JB, Mahan CM, Charles D, Dandrow RV. Screening criteria for high-risk gestational diabetic patients. Am J Obstet Gynecol 1973; 116:895.</a></li><li class="breakAll">Screening for Gestational Diabetes Mellitus: A Systematic Review to Update the 2014 U.S. Preventive Services Task Force Recommendation, Pillay J, Donovan L, Guitard S, Zakher B, Korownyk C, Gates M, Gates A, Vandermeer B, Bougatsos C, Chou R, Hartling L. (Eds), Agency for Healthcare Research and Quality (US), Rockville (MD) 2021.</li><li><a class="nounderline abstract_t">Lanni S, Barrett D. The predictive value of the 1-h 50-g glucose screen for diagnosing gestational diabetes mellitus in a high-risk population. J Matern Fetal Neonatal Med 2004; 15:375.</a></li><li><a class="nounderline abstract_t">Cheng YW, Esakoff TF, Block-Kurbisch I, et al. Screening or diagnostic: markedly elevated glucose loading test and perinatal outcomes. J Matern Fetal Neonatal Med 2006; 19:729.</a></li><li><a class="nounderline abstract_t">Conn JW. Interpretation of the glucose tolerance test: Necessity of standard preparatory diet. Am J Med Sci 1940; 199:555.</a></li><li><a class="nounderline abstract_t">Crowe SM, Mastrobattista JM, Monga M. Oral glucose tolerance test and the preparatory diet. Am J Obstet Gynecol 2000; 182:1052.</a></li><li><a class="nounderline abstract_t">Entrekin K, Work B, Owen J. Does a high carbohydrate preparatory diet affect the 3-hour oral glucose tolerance test in pregnancy? J Matern Fetal Med 1998; 7:68.</a></li><li><a class="nounderline abstract_t">Harlass FE, McClure GB, Read JA, Brady K. Use of a standard preparatory diet for the oral glucose tolerance test. Is it necessary? J Reprod Med 1991; 36:147.</a></li><li><a class="nounderline abstract_t">Riccardi G, Vaccaro O, Rivellese A, et al. Reproducibility of the new diagnostic criteria for impaired glucose tolerance. Am J Epidemiol 1985; 121:422.</a></li><li><a class="nounderline abstract_t">Harlass FE, Brady K, Read JA. Reproducibility of the oral glucose tolerance test in pregnancy. Am J Obstet Gynecol 1991; 164:564.</a></li><li><a class="nounderline abstract_t">Potter JM, Hickman PE, Oakman C, et al. Strict Preanalytical Oral Glucose Tolerance Test Blood Sample Handling Is Essential for Diagnosing Gestational Diabetes Mellitus. Diabetes Care 2020; 43:1438.</a></li><li><a class="nounderline abstract_t">Agarwal MM, Punnose J, Dhatt GS. Gestational diabetes: problems associated with the oral glucose tolerance test. Diabetes Res Clin Pract 2004; 63:73.</a></li><li><a class="nounderline abstract_t">Fachnie JD, Whitehouse FW, McGrath Z. Vomiting during OGTT in third trimester of pregnancy. Diabetes Care 1988; 11:818.</a></li><li><a class="nounderline abstract_t">Schwartz JG, Phillips WT, Blumhardt MR, Langer O. Use of a more physiologic oral glucose solution during screening for gestational diabetes mellitus. Am J Obstet Gynecol 1994; 171:685.</a></li><li><a class="nounderline abstract_t">Powe CE, Locascio JJ, Gordesky LH, et al. Oral Glucose Tolerance Test-based Measures of Insulin Secretory Response in Pregnancy. J Clin Endocrinol Metab 2022; 107:e1871.</a></li><li><a class="nounderline abstract_t">Guelinckx I, Devlieger R, Vansant G. Reproductive outcome after bariatric surgery: a critical review. Hum Reprod Update 2009; 15:189.</a></li><li><a class="nounderline abstract_t">Lamar ME, Kuehl TJ, Cooney AT, et al. Jelly beans as an alternative to a fifty-gram glucose beverage for gestational diabetes screening. Am J Obstet Gynecol 1999; 181:1154.</a></li><li><a class="nounderline abstract_t">Murphy NJ, Meyer BA, O'Kell RT, Hogard ME. Carbohydrate sources for gestational diabetes mellitus screening. A comparison. J Reprod Med 1994; 39:977.</a></li><li><a class="nounderline abstract_t">Court DJ, Mann SL, Stone PR, et al. Comparison of glucose polymer and glucose for screening and tolerance tests in pregnancy. Obstet Gynecol 1985; 66:491.</a></li><li><a class="nounderline abstract_t">Bergus GR, Murphy NJ. Screening for gestational diabetes mellitus: comparison of a glucose polymer and a glucose monomer test beverage. J Am Board Fam Pract 1992; 5:241.</a></li><li><a class="nounderline abstract_t">Reece EA, Holford T, Tuck S, et al. Screening for gestational diabetes: one-hour carbohydrate tolerance test performed by a virtually tasteless polymer of glucose. Am J Obstet Gynecol 1987; 156:132.</a></li><li><a class="nounderline abstract_t">Racusin DA, Antony K, Showalter L, et al. Candy twists as an alternative to the glucola beverage in gestational diabetes mellitus screening. Am J Obstet Gynecol 2015; 212:522.e1.</a></li><li><a class="nounderline abstract_t">Zhu WW, Fan L, Yang HX, et al. Fasting plasma glucose at 24-28 weeks to screen for gestational diabetes mellitus: new evidence from China. Diabetes Care 2013; 36:2038.</a></li><li><a class="nounderline abstract_t">Sacks DA, Hadden DR, Maresh M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. Diabetes Care 2012; 35:526.</a></li><li><a class="nounderline abstract_t">Buhling KJ, Elze L, Henrich W, et al. The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes. Eur J Obstet Gynecol Reprod Biol 2004; 113:145.</a></li><li><a class="nounderline abstract_t">Watson WJ. Screening for glycosuria during pregnancy. South Med J 1990; 83:156.</a></li><li><a class="nounderline abstract_t">Gribble RK, Meier PR, Berg RL. The value of urine screening for glucose at each prenatal visit. Obstet Gynecol 1995; 86:405.</a></li><li><a class="nounderline abstract_t">O'SULLIVAN JB, MAHAN CM. CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY. Diabetes 1964; 13:278.</a></li><li><a class="nounderline abstract_t">Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005; 352:2477.</a></li><li><a class="nounderline abstract_t">Roeckner JT, Sanchez-Ramos L, Jijon-Knupp R, Kaunitz AM. Single abnormal value on 3-hour oral glucose tolerance test during pregnancy is associated with adverse maternal and neonatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 215:287.</a></li><li><a class="nounderline abstract_t">Selen DJ, Thaweethai T, Schulte CCM, et al. Gestational Glucose Intolerance and Risk of Future Diabetes. Diabetes Care 2023; 46:83.</a></li><li><a class="nounderline abstract_t">Caissutti C, Khalifeh A, Saccone G, Berghella V. Are women positive for the One Step but negative for the Two Step screening tests for gestational diabetes at higher risk for adverse outcomes? Acta Obstet Gynecol Scand 2018; 97:122.</a></li><li><a class="nounderline abstract_t">Noctor E, Crowe C, Carmody LA, et al. ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria. Acta Diabetol 2015; 52:153.</a></li><li><a class="nounderline abstract_t">Lowe WL Jr, Scholtens DM, Lowe LP, et al. Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity. JAMA 2018; 320:1005.</a></li><li><a class="nounderline abstract_t">Crowther CA, Samuel D, McCowan LME, et al. Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. N Engl J Med 2022; 387:587.</a></li><li><a class="nounderline abstract_t">de Wit L, Bos DM, van Rossum AP, et al. Repeated oral glucose tolerance tests in women at risk for gestational diabetes mellitus. Eur J Obstet Gynecol Reprod Biol 2019; 242:79.</a></li><li><a class="nounderline abstract_t">Kurtbas H, Keskin HL, Avsar AF. Effectiveness of screening for gestational diabetes during the late gestational period among pregnant Turkish women. J Obstet Gynaecol Res 2011; 37:520.</a></li><li><a class="nounderline abstract_t">Boriboonhirunsarn D, Sunsaneevithayakul P. Abnormal results on a second testing and risk of gestational diabetes in women with normal baseline glucose levels. Int J Gynaecol Obstet 2008; 100:147.</a></li><li><a class="nounderline abstract_t">Seshiah V, Balaji V, Balaji MS, et al. Gestational diabetes mellitus manifests in all trimesters of pregnancy. Diabetes Res Clin Pract 2007; 77:482.</a></li><li><a class="nounderline abstract_t">Farrar D, Duley L, Medley N, Lawlor DA. Different strategies for diagnosing gestational diabetes to improve maternal and infant health. Cochrane Database Syst Rev 2015; 1:CD007122.</a></li><li class="breakAll">World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy, 2013. http://www.who.int/diabetes/publications/Hyperglycaemia_In_Pregnancy/en/index.html (Accessed on August 26, 2013).</li><li><a class="nounderline abstract_t">Hod M, Pretty M, Mahmood T, FIGO, EAPM and EBCOG. Joint position statement on universal screening for GDM in Europe by FIGO, EBCOG and EAPM. Eur J Obstet Gynecol Reprod Biol 2018; 228:329.</a></li></ol></div><div id="topicVersionRevision">Topic 6797 Version 146.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9841138" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38078589" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29370047" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7148898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Criteria for screening tests for gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35877134" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Trends and Characteristics in Gestational Diabetes: United States, 2016-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33741696" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Resolving the Gestational Diabetes Diagnosis Conundrum: The Need for a Randomized Controlled Trial of Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20190296" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300020" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Global estimates of the prevalence of hyperglycaemia in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18279822" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Gestational diabetes in the United States: temporal trends 1989 through 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067968" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diabetes trends among delivery hospitalizations in the U.S., 1994-2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23947320" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Fraction of gestational diabetes mellitus attributable to overweight and obesity by race/ethnicity, California, 2007-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24705609" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Trends in incidence of diabetes in pregnancy and serious perinatal outcomes: a large, population-based study in Ontario, Canada, 1996-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25398676" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A population-based observational study of diabetes during pregnancy in Victoria, Australia, 1999-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34402831" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Trends in Gestational Diabetes at First Live Birth by Race and Ethnicity in the US, 2011-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36280146" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Trends in gestational diabetes mellitus among nulliparous pregnant individuals with singleton live births in the United States between 2011 to 2019: an age-period-cohort analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37072237" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The effect of changing screening practices and demographics on the incidence of gestational diabetes in British Columbia, 2005-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35412565" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of Adverse Pregnancy Outcomes Among Pregnant Individuals With Gestational Diabetes by Race and Ethnicity in the United States, 2014-2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35613728" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463375" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hyperglycemia and adverse pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21309194" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The relationship between maternal glycemia and perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27624087" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hyperglycaemia and risk of adverse perinatal outcomes: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37539973" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gestational Glucose Intolerance and Birth Weight-Related Complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35104296" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risks of specific congenital anomalies in offspring of women with diabetes: A systematic review and meta-analysis of population-based studies including over 80 million births.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28120287" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pre-pregnancy Obesity as a Modifier of Gestational Diabetes and Birth Defects Associations: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19211471" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25871668" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Association of maternal diabetes with autism in offspring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26826214" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The Association of Maternal Obesity and Diabetes With Autism and Other Developmental Disabilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24057131" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Maternal diabetes and the risk of autism spectrum disorders in the offspring: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25783684" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of maternal diabetes on the embryo, fetus, and children: congenital anomalies, genetic and epigenetic changes and developmental outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30655380" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617141" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS): Maternal Glycemia and Childhood Glucose Metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9315766" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A prospective study of pregravid determinants of gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The Risk Factors of Gestational Diabetes Mellitus: A</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19691951" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Does frank diabetes in first-degree relatives of a pregnant woman affect the likelihood of her developing gestational diabetes mellitus or nongestational diabetes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18068138" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Body mass index and weight gain prior to pregnancy and risk of gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177292" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Gestational weight gain and risk of gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22353954" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Maternal weight gain in women who develop gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22617588" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Excessive early gestational weight gain and risk of gestational diabetes mellitus in nulliparous women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33980302" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The risk of diabetes after giving birth to a macrosomic infant: data from the NHANES cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20630491" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gestational diabetes: risk of recurrence in subsequent pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24423035" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Screening and diagnosing gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10521732" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Universal versus selective gestational diabetes screening: application of 1997 American Diabetes Association recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30216635" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Improving the effectiveness of lifestyle interventions for gestational diabetes prevention: a meta-analysis and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20670854" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reduced incidence of gestational diabetes with bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28029178" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exercise during pregnancy and risk of preterm birth in overweight and obese women: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25730218" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Physical activity interventions in pregnancy and risk of gestational diabetes mellitus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26036300" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effectiveness of physical activity interventions on preventing gestational diabetes mellitus and excessive maternal weight gain: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36156844" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Exercise during pregnancy for preventing gestational diabetes mellitus and hypertensive disorders: An umbrella review of randomised controlled trials and an updated meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25719363" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Nutritional manipulation for the primary prevention of gestational diabetes mellitus: a meta-analysis of randomised studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26696657" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The Role of Energy, Nutrients, Foods, and Dietary Patterns in the Development of Gestational Diabetes Mellitus: A Systematic Review of Observational Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28046205" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dietary advice interventions in pregnancy for preventing gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14578229" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cigarette smoking and the risk of gestational and pregestational diabetes in two consecutive pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25706240" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program outcomes study 10-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11872206" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17678910" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926533" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26840133" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26165398" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effect of metformin on maternal and fetal outcomes in obese pregnant women (EMPOWaR): a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33870484" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Probiotics for preventing gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36790138" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34374716" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34374717" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Screening for Gestational Diabetes: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385666" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Impact of the creation of a specialized clinic for prenatal blood sampling and follow-up care in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30891907" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Gestational diabetes and the risk of late stillbirth: a case-control study from England, UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22099435" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27917777" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34486452" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of the GeDiForCE model in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067953" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29358466" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Discovery, Knowledge, and Action-Diabetes in Pregnancy Across the Translational Spectrum: The 2016 Norbert Freinkel Award Lecture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396914" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Congenital malformations in offspring of women with hyperglycemia first detected during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16186312" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Proposal for the reconsideration of the definition of gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423854" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Maternal diabetes mellitus and infant malformations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36031150" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Early screening for gestational diabetes mellitus: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16093576" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : HbA1c in healthy, pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24912095" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37144983" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31926951" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Early gestational diabetes screening in obese women: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12512927" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Glucose screening test results in first and early third trimester of pregnancy: is there any correlation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2216208" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Correlation between first- and early third-trimester glucose screening test results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757431" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Applying current screening tools for gestational diabetes mellitus to a European population: is it time for change?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21489844" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Universal two-step screening strategy for gestational diabetes has weak relevance in French Mediterranean women: should we simplify the screening strategy for gestational diabetes in France?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384264" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Risk factor screening to identify women requiring oral glucose tolerance testing to diagnose gestational diabetes: A systematic review and meta-analysis and analysis of two pregnancy cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26796129" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diagnostic ability of elevated 1-h glucose challenge test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Diabetes and pregnancy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28326332" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Quality of Life in Women with Gestational Diabetes Mellitus: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32028931" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Women's experiences of a diagnosis of gestational diabetes mellitus: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36201775" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : More Is Not Always Better.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34023312" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : One-step or 2-step testing for gestational diabetes: which is better?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4718216" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Screening criteria for high-risk gestational diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4718216" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Screening criteria for high-risk gestational diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15280108" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The predictive value of the 1-h 50-g glucose screen for diagnosing gestational diabetes mellitus in a high-risk population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17127496" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Screening or diagnostic: markedly elevated glucose loading test and perinatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Interpretation of the glucose tolerance test: Necessity of standard preparatory diet</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10819825" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Oral glucose tolerance test and the preparatory diet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9584817" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Does a high carbohydrate preparatory diet affect the 3-hour oral glucose tolerance test in pregnancy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2010899" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Use of a standard preparatory diet for the oral glucose tolerance test. Is it necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4014132" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Reproducibility of the new diagnostic criteria for impaired glucose tolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1992702" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Reproducibility of the oral glucose tolerance test in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350020" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Strict Preanalytical Oral Glucose Tolerance Test Blood Sample Handling Is Essential for Diagnosing Gestational Diabetes Mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693415" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Gestational diabetes: problems associated with the oral glucose tolerance test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3246204" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Vomiting during OGTT in third trimester of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8092215" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Use of a more physiologic oral glucose solution during screening for gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35090176" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Oral Glucose Tolerance Test-based Measures of Insulin Secretory Response in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19136457" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Reproductive outcome after bariatric surgery: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561636" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Jelly beans as an alternative to a fifty-gram glucose beverage for gestational diabetes screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7884757" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Carbohydrate sources for gestational diabetes mellitus screening. A comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4047540" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Comparison of glucose polymer and glucose for screening and tolerance tests in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1580171" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Screening for gestational diabetes mellitus: comparison of a glucose polymer and a glucose monomer test beverage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799747" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Screening for gestational diabetes: one-hour carbohydrate tolerance test performed by a virtually tasteless polymer of glucose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25446695" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Candy twists as an alternative to the glucola beverage in gestational diabetes mellitus screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23536582" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Fasting plasma glucose at 24-28 weeks to screen for gestational diabetes mellitus: new evidence from China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22355019" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15063950" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : The usefulness of glycosuria and the influence of maternal blood pressure in screening for gestational diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2305295" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Screening for glycosuria during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7651652" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The value of urine screening for glucose at each prenatal visit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14166677" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : CRITERIA FOR THE ORAL GLUCOSE TOLERANCE TEST IN PREGNANCY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15951574" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of treatment of gestational diabetes mellitus on pregnancy outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27133007" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Single abnormal value on 3-hour oral glucose tolerance test during pregnancy is associated with adverse maternal and neonatal outcomes: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36473077" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Gestational Glucose Intolerance and Risk of Future Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091257" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Are women positive for the One Step but negative for the Two Step screening tests for gestational diabetes at higher risk for adverse outcomes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25002067" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : ATLANTIC-DIP: prevalence of metabolic syndrome and insulin resistance in women with previous gestational diabetes mellitus by International Association of Diabetes in Pregnancy Study Groups criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30208453" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Association of Gestational Diabetes With Maternal Disorders of Glucose Metabolism and Childhood Adiposity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36070709" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31569028" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Repeated oral glucose tolerance tests in women at risk for gestational diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349129" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Effectiveness of screening for gestational diabetes during the late gestational period among pregnant Turkish women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18005964" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Abnormal results on a second testing and risk of gestational diabetes in women with normal baseline glucose levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17292506" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Gestational diabetes mellitus manifests in all trimesters of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604891" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Different strategies for diagnosing gestational diabetes to improve maternal and infant health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25604891" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Different strategies for diagnosing gestational diabetes to improve maternal and infant health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895471" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Joint position statement on universal screening for GDM in Europe by FIGO, EBCOG and EAPM.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
